Belgium biotech Agomab outlines up to $212M Nasdaq debut to fund immunology trials
Belgium biotech Agomab outlines up to $212M Nasdaq debut to fund immunology trials
Belgium biotech Agomab outlines up to $212M Nasdaq debut to fund immunology trials
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.